Our lead program candidate, STAR-0215, is a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, safe, and effective attack prevention for HAE, with potential for dosing once every 3 or 6 months. We shared positive preliminary results from our Phase 1a clinical trial in healthy subjects in 2022, and initiated the proof-of-concept ALPHA-STAR trial in people living with HAE in early 2023. Initial proof-of-concept results in HAE patients from single and multiple dose cohorts are expected in mid-2024.
